基于甲状腺癌谷胱甘肽代谢建立预后分层模型并验证RRM2的肿瘤促进作用

Developing a prognostic stratification model based on glutathione metabolism in thyroid cancer and validating RRM2's tumor-promoting role.

作者信息Wei Ao, Teng-Hong Liu, De-Tao Yin, Wen-Xin Zhao
PMID41333212
发布时间2025-11-17
DOI10.3389/fonc.2025.1700439

实验完整度

包含TCGA队列生物信息学分析、细胞功能实验(CCK-8、克隆形成、迁移侵袭、凋亡、细胞周期)、裸鼠皮下成瘤及mRNA测序等多层级体外和体内验证。

主要模型

PTC细胞系TPC-1 PTC细胞系IHH4 BALB/c裸鼠皮下移植瘤模型 44例PTC患者肿瘤及配对癌旁组织

重点核对

TCGA队列中510例THCA患者RNA-seq数据及临床信息 LASSO Cox回归模型构建及风险评分分组(按中位风险评分) RRM2过表达和敲低细胞系的构建(慢病毒转染) 裸鼠皮下成瘤实验(每组6只,接种2×10^6细胞) RRM2表达与DFS的相关性分析

摘要

Introduction: Glutathione (GSH), the most abundant antioxidant in cells, acts as free radical scavenger and detoxifying agent. Elevation of GSH metabolism protects tumor from damage of oxidant and even promotes tumor progression. However, the clinical value of GSH metabolism in thyroid cancer (THCA) remained largely unknown.Methods: The expression and prognostic value of GSH metabolism-related enzymes were first investigated using a large The Cancer Genome Atlas (TCGA) cohort of 510 THCA patients. To expand the prognostic application, a risk stratification model based on these enzymes was developed using the LASSO Cox regression algorithm. Patients were categorized into high- and low-risk groups based on the median risk score, and the model's predictive performance for disease-freesurvival (DFS) was validated. Further correlation analysis, pan-cancer analysis (using TCGA and GTEx data), and detailed analysis across pathological types and TNM stages were performed to identify and characterize key molecules, such as RRM2. Finally, the biological role of RRM2 was validated in vitro (CCK-8 and colony-formation assays) and in vivo (subcutaneous tumor formation in nude mice). Furthermore, the molecular mechanism underlying RRM2's tumor-promoting function was preliminarily investigated through mRNA sequencing and subsequent experiments.Results: The majority of GSH metabolism-related enzymes were significantly upregulated in THCA tumor tissues and their expression was negatively associated with DFS. The LASSO Cox model stratified patients into high-risk and low-risk groups with significantly different DFS. High-risk status was also positively correlated with increased infiltration of naïve B cells, activated memory CD4+ T cells, helper T cells and regulatory T cells. RRM2, screened as a key molecule, exhibited high expression in THCA tissues, especially in more aggressive subtypes (classic and tall-cell variants of papillary THCA) and N stages. Paired-sample IHC confirmed higher RRM2 in PTC versus adjacent tissue. High RRM2 expression was significantly and negatively correlated with DFS. Functionally, RRM2 overexpression promoted TPC-1 cell proliferation and colony formation (CCK-8 and colony assays) while knockdown suppressed growth. Subcutaneous tumor formation experiments recapitulated these findings. Mechanistically, RRM2's oncogenic effects may be mediated through cell cycle regulation and activation of the PI3K/Akt signaling pathway.Discussion: GSH metabolism-related enzymes are upregulated in THCA and associate with a worse prognosis and an immune landscape suggestive of antigenic stimulation coupled with immunosuppression. RRM2 is a tumor-promoting gene that correlates with aggressive clinicopathologic features and functionally drives thyroid tumor growth in vitro and in vivo. These data support further investigation of GSH metabolism and RRM2 as prognostic biomarkers and potential therapeutic targets in thyroid cancer.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
GSH代谢相关酶在甲状腺癌中的表达及其预后价值,以及关键分子RRM2在PTC发生发展中的功能与机制。
核心机制
RRM2可能通过调控细胞周期(G1/S期转变)和激活PI3K/Akt信号通路,并诱导EMT过程,从而促进甲状腺癌细胞的增殖、迁移和侵袭。
主要证据
TCGA队列分析显示GSH代谢酶高表达与较差DFS相关,LASSO Cox模型风险分层有效;细胞实验表明RRM2过表达促进增殖、迁移、侵袭并抑制凋亡,敲低则相反;裸鼠成瘤实验证实RRM2促进肿瘤生长;mRNA测序和Western blot显示RRM2影响细胞周期相关蛋白及PI3K/Akt通路(pAkt、PI3K p85α、p110α上调)。
研究意义
研究表明GSH代谢相关酶和RRM2可作为甲状腺癌的预后生物标志物和潜在治疗靶点,支持进一步研究。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

生物信息学分析与风险模型构建

评估GSH代谢相关酶在THCA中的表达和预后价值,并构建风险分层模型。

利用TCGA(510例THCA)和GTEx(58例正常甲状腺)数据,分析24种GSH代谢相关酶的表达差异及与DFS的关系;通过LASSO Cox回归构建9基因风险模型,并按中位风险评分将患者分为高低风险组。

2

临床样本验证RRM2表达

验证RRM2在PTC组织与配对癌旁组织中的表达差异及其与临床特征的关系。

收集44例PTC患者肿瘤及配对癌旁组织,采用RT-qPCR和免疫组化检测RRM2 mRNA和蛋白表达,并分析其与临床病理特征的相关性。

3

体外细胞功能实验

评估RRM2过表达或敲低对PTC细胞增殖、迁移、侵袭、凋亡和细胞周期的影响。

在TPC-1和IHH4细胞中建立RRM2过表达(RRM2-OE)和敲低(RRM2-KD)稳定系,通过CCK-8、克隆形成、划痕愈合、Transwell、流式细胞术及Western blot检测相关表型和蛋白表达。

4

体内裸鼠成瘤实验

验证RRM2对PTC细胞体内肿瘤生长的影响。

将TPC-1、RRM2-KD-TPC-1和RRM2-OE-TPC-1细胞皮下接种于裸鼠,监测肿瘤生长曲线、体积和重量,并通过IHC检测Ki67、PCNA和RRM2表达。

5

转录组测序及机制探索

探索RRM2过表达后的转录组变化及潜在分子机制。

对TPC-1和RRM2-OE-TPC-1细胞进行mRNA测序,筛选差异表达基因并进行GO和KEGG富集分析,随后通过Western blot验证细胞周期和PI3K/Akt通路相关蛋白。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
RPMI 1640培养基Gibco, Thermo Fisher Scientific--
胎牛血清TYCOTO; China Hanqiang (Guangzhou) Biotechnology Co.--
恒湿培养箱Thermo Fisher Scientific--
TRIzol试剂Invitrogen; Thermo Fisher Scientific15596018
All-In-One 5X RT MasterMix逆转录预混液abmG592
PerfectStart® Green qPCR SuperMixBeijing TransGen Biotech CoAQ602
StepOnePlus实时荧光定量PCR系统Applied Biosystems, Thermo Fisher Scientific4376592
抗人/小鼠RRM2抗体Abcamab172476
抗小鼠PCNA抗体Maixin Bio-technology Development CompanyRMA-0145
抗小鼠Ki-67抗体Maixin Bio-technology Development CompanyRMA-0731
Elivision™ Plus免疫组化检测系统Maixin Biotechkit9903
增强型BCA蛋白定量试剂盒BOSTER Biological Technology coAR0197A
聚偏二氟乙烯膜MilliporeIPVH00010
无蛋白快速封闭液Wuhan Boster Biological Technology Co., Ltd.AR0041
抗人GAPDH抗体Proteintech10494
山羊抗兔IgG H&L(HRP)Abcamab205718
山羊抗小鼠IgG H&L(HRP)Abcamab97023
高效化学发光试剂盒Beijing Dingguo Changsheng Biotech CoGE2301
抗人Bax抗体CST5023
抗人Bcl-2抗体CST3498
抗人MMP2抗体CST40994
抗人MMP9抗体CST13667
抗人N-钙黏蛋白抗体CST13116
抗人波形蛋白抗体CST5741
抗人Snail抗体CST3879
抗人Akt抗体CST4691
抗人磷酸化Akt抗体CST4060
抗人PI3K激酶p110α抗体CST4249
抗人PTEN抗体CST9188
抗人PI3K激酶p85α+p55抗体Abcamab278545
抗人Cyclin A2抗体Proteintech18202
抗人Cyclin E2抗体Proteintech11935
抗人CDK2抗体Proteintech10122
抗人c-MYC抗体Proteintech10828
抗人Cyclin D1抗体Proteintech60186
聚凝胺SigmaH9268
嘌呤霉素BeyotimeST551
细胞计数试剂盒-8DojindoCK04
多功能酶标仪BioTek Instruments Inc.--
APC-Annexin V结合凋亡检测试剂盒ElabscienceE-CK-A218
碘化丙啶和RNase AElabscienceE-CK-A351
流式细胞仪(C6 plus)----
FlowJo v7.6.1软件BD Life Sciences--
Matrigel基质胶Corning354234
24孔小室Corning3422
NEBNext® Ultra™定向RNA文库制备试剂盒(Illumina)New England Biolabs--
Illumina NovaSeq 6000测序平台Novogene Co., Ltd.--
Agilent 2100生物分析仪Agilent Technologies--

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
生物信息学分析
TCGA数据版本(UCSC Xena)、GTEx数据版本、GSH代谢酶基因列表(24个)、LASSO Cox参数、训练/验证集划分
阅读提示:Materials and methods: 2.1-2.4
临床样本验证
样本量44例、患者年龄范围、配对组织、RT-qPCR条件和引物序列、IHC染色评分标准
阅读提示:Materials and methods: 2.7, 2.8; Results: 3.5
体外细胞功能实验
细胞系来源及培养条件、慢病毒转染MOI、筛选浓度、细胞接种密度、检测时间点
阅读提示:Materials and methods: 2.5, 2.10-2.17
体内成瘤实验
小鼠品系、周龄、性别、每组数量、细胞接种量、肿瘤测量时间、终止时间
阅读提示:Materials and methods: 2.13; Results: 3.4
转录组测序
细胞系、测序平台、文库构建方法、差异分析阈值、富集分析工具
阅读提示:Materials and methods: 2.18